Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Senti Biosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: Senti issued a press release on April 28, 2025, reporting that “enrollment has been stopped” in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A, conducted in collaboration with Celes Therapeutics (Shanghai) Co. Ltd., “[b]ased on the observation of certain dose limiting toxicities[.]” Following this news, Senti’s stock price fell over 27% on the same day.
In order to be eligible to join the SNTI class action lawsuit, you must have incurred a loss on shares of Senti Biosciences, Inc. purchased during the class period listed above.
TOP
